Cellular uptake and localization of liposomal-methylphoshonate oligodeoxynucleotides

Journal of Molecular Medicine

Volumn 74, Issue 10, 1996, Pages 623-628

  Tari, A M ^a   Andreeff, M ^a   Kleine, H D ^a   Lopez Berestein, G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antisense; Liposomes; Methylphosphonates; Oligodeoxynucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; METHYLPHOSPHONIC ACID; OLIGODEOXYNUCLEOTIDE;

ARTICLE; DRUG UPTAKE; HUMAN; HUMAN CELL;

DRUG CARRIERS; HL-60 CELLS; HUMANS; LIPOSOMES; OLIGONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0029853140     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050066     Document Type: Article

References (27)

1. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335
2. Stein CA (1994) Antisense Oligodeoxynucleotides as therapeutic agents. Contemporary Oncol 4:31-39
3. Stein CA, Narayanan R (1994) Antisense oligodeoxynucleotides. Curr Opin Oncol 6:587-594
4. Tari AM, Lopez-Berestein G (1993) Antisense oligonucleotides and carriers for gene therapy. Cancer Bull 45:164-170
5. Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic anents - is the bullet really magical? Science 261:1004-1012
6. Akhtar A, Shoji Y, Julian RL (1992) Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA. Raven, New York, pp 133-145
7. Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 48:2659-2668
8. Szczylik C, Skorski T, Nicolaides NC, Manzella LM, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B (1991) Selective inhibition of leukemia cell proliferation by Bcr-Abl antisense Oligodeoxynucleotides. Science 253:562-565
9. Skorski T, Szczylik C, Malaguarnera L, Calabretta B (1992) Gene-trageted specific inhibition of chronic myeloid cell growth by Bcr-Abl antisense Oligodeoxynucleotides. Folia Histochem Cytobiol 29:85-90
10. Eder PS, DeVine RJ, Dagle, JM, Walder JA (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1:141-151
11. Zamecnik PC, Goodchild J, Yaguchi Y, Sarin P (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 83:4143-4146
12. Miller PS, McParland KB, Jayaraman K, T'so POP 1981 Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20:1874-1880
13. Thierry AR, Dritschilo A (19992) Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20:5691-5698
14. Tonkinson JL, Stein CA (1994) Patterns of intracellular compartmentalization trafficking and acidification of 5′-fluorescein-labeled phosphodiester and phosphorothioate oligonucleotides in HL60 cells. Nucleic Acids Res 22:4268-4275
15. Akhtar S, Basu S, Wickstrom E, Juliano RL (1991) Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res 19:5551-5559
16. Wickstrom E (1992) Antisense DNA therapeutics: Neutral analogs and their stereochemistry. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA. Raven, New York, pp 119-132
17. Ropert C, Malvy C, Couvreur P (1993) Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharm Res 10:1427-1433
18. Thierry AR, Rahman A, Dritschilo A (1993) Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 190:952-960
19. Bennett CF, Chiang MY, Chan H, Shoemaker JEE, Mirabelli C (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033
20. Busch RK, Perlaky L, Valdez BC, Henning D, Busch H (1994) Apoptosis in human tumor cells following treatment with p120 antisense oligodeoxynucleotide ISIS 3466. Cancer Lett 86: 151-157
21. Lappalainen K, Urtti A, Soderling E, Jaaskelainen I, Syrjanen K, Syrjanen S (1994) Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1196:201-208
22. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestien G (1994) Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 84: 601-607
23. Mehta K, Lopez-Berestein G, Hersh EM, Juliano R 1992 Uptake of liposome and liposome-encapsulated muramyl dipeptide by human monocytes. J Reticuloendothelial Soc 32:155-164
24. Tari AM, Fuller N, Boni LT, Collins D, Rand, P, Huang, L (1994) Interactions of liposome biolayers composed of 1,2-diacyl-3-succinylglycerol with protons and divalent cations. Biochim Biophys Acta 1192:253-262
25. Huang A, Kennel S, Huang L (1983) Interactions of immunoliposomes with target cells. J Biol Chem 258:14034-14040
26. Perez-Soler R, Khokhar AR, Lopez-Berestein G (1987) Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R, R-1, 2-diaminocycolhexaneplatinum (II) encapsulated in multilamellar vesicles. Cancer Res 47:6462-6466
27. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniea J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff IH (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7:1915-1925